A small open-label study evaluating the epilepsy medication perampanel in adults with amyotrophic lateral sclerosis (ALS) was halted due to adverse events that affected behavior. Despite the findings, larger clinical trials investigating perampanel in ALS patients are ongoing, which might determine if the medication contributed to behavioral side effects. The…

AC Immune has extended its research collaboration with scientists at the University of Pennsylvania (UPenn) working to uncover how TDP-43 protein clumps contribute to different disease manifestations in amyotrophic lateral sclerosis (ALS). In the partnership’s first two years, researchers with the Perelman School of Medicine at UPenn received…

CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), failed to prevent motor neurons loss and lung function decline relative to a placebo, according to top-line data from the RESCUE-ALS Phase 2 clinical trial. The trial, in other words, did not meet its primary…

Age, socioeconomic status, and co-existing conditions are among the factors that can lead to a need for assisted ventilation in people with amyotrophic lateral sclerosis (ALS), research from Korea reports. The study, “Factors associated with assisted ventilation use in amyotrophic lateral sclerosis: a nationwide population-based study in Korea,”…

Certain blood biomarkers of lipid, or fat, metabolism — typically measured to determine a person’s risk of cardiovascular disease — appear to protect against developing amyotrophic lateral sclerosis (ALS), a study of more than 500,000 adults reported. Specifically, researchers found that people with higher levels of high density lipoprotein (HDL)…

Last week for me, the letters A-L-S stood for “A Lot of Socks.” I tackled a project that would make living with amyotrophic lateral sclerosis easier for me right now, for my future self, gave me peace of mind, and yes, it involved socks. It all began when I was…

Using a new laboratory model of brain cells, researchers demonstrated that cells with mutations associated with amyotrophic lateral sclerosis (ALS) show early signs of DNA damage and other forms of cellular stress. Results suggest that blocking these cellular stress processes may hold promise in treating ALS. The study, “…

New early clinical study results support the potential of GN-K01, an investigational antibody being developed by GeNeuro, as a treatment for amyotrophic lateral sclerosis (ALS). The therapy may enter clinical trials as early as 2022, according to the company. The antibody targets a viral protein, called HERV-K ENV,…

Tofersen, an experimental treatment for amyotrophic lateral sclerosis (ALS) patients with mutations in the SOD1 gene, failed to significantly slow the rate of disease progression relative to a placebo in a Phase 3 trial. These top-line findings mean that the VALOR study (NCT02623699), which is testing tofersen in…

Like most folks who live with ALS, I tend to get stuck in the shortsighted day-to-day management of my symptoms. Over the years, I’ve developed several strategies that help me change my mental focus from a short view to a longer one in which I’m open to the possibilities of…